Next Article in Journal
Entrapment of Hydrophilic and Hydrophobic Molecules in Beads Prepared from Isolated Denatured Whey Protein
Next Article in Special Issue
Development and Evaluations of Transdermally Delivered Luteolin Loaded Cationic Nanoemulsion: In Vitro and Ex Vivo Evaluations
Previous Article in Journal
Hydroxycinnamic Acids and Derivatives Formulations for Skin Damages and Disorders: A Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 7
10.3390/pharmaceutics13071000
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio

by
Omar Ulises Cruz-Ramírez
1,
Lucía Margarita Valenzuela-Salas
2,
Alberto Blanco-Salazar
3,4,
José Antonio Rodríguez-Arenas
3,4,
Paris A. Mier-Maldonado
2,
Juan Carlos García-Ramos
4,*,
Nina Bogdanchikova
1,
Alexey Pestryakov
5 and
Yanis Toledano-Magaña
4,*
1
Centro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Ensenada 22860, Mexico
2
Facultad de Ciencias de la Salud Unidad Valle de las Palmas, Universidad Autónoma de Baja California, Tijuana 22260, Mexico
3
Programa de Maestría y Doctorado en Ciencias e Ingeniería, Facultad de Ciencias, Universidad Autónoma de Baja California, Ensenada 22860, Mexico
4
Escuela de Ciencias de la Salud Unidad Valle Dorado, Universidad Autónoma de Baja California, Ensenada 22890, Mexico
5
Research School of Chemistry & Applied Biomedical Sciences, National Research Tomsk Polytechnic University, 634050 Tomsk, Russia
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2021, 13(7), 1000; https://doi.org/10.3390/pharmaceutics13071000
Submission received: 26 May 2021 / Revised: 23 June 2021 / Accepted: 28 June 2021 / Published: 1 July 2021
(This article belongs to the Special Issue Nanocarriers for Cancer Therapy and Diagnosis)
Browse Figures
Versions Notes

Abstract

:
Silver nanoparticles (AgNPs) not only have shown remarkable results as antimicrobial and antiviral agents but also as antitumor agents. This work reports the complete characterization of five polyvinylpyrrolidone-coated AgNP (PVP-AgNP) formulations, their cytotoxic activity against human colon tumor cells (HCT-15), their cytotoxic effect on primary mouse cultures, and their lethal dose on BALB/c mice. The evaluated AgNP formulations have a composition within the ranges Ag: 1.14–1.32% w/w, PVP: 19.6–24.5% and H2O: 74.2–79.2% with predominant spherical shape within an average size range of 16–30 nm according to transmission electron microscopy (TEM). All formulations assessed increase mitochondrial ROS concentration and induce apoptosis as the leading death pathway on HCT-15 cells. Except for AgNP1, the growth inhibition potency of AgNP formulations of human colon tumor cancer cells (HCT-15) is 34.5 times higher than carboplatin, one of the first-line chemotherapy agents. Nevertheless, 5–10% of necrotic events, even at the lower concentration evaluated, were observed. The cytotoxic selectivity was confirmed by evaluating the cytotoxic effect on aorta, spleen, heart, liver, and kidney primary cultures from BALB/c mice. Despite the cytotoxic effects observed in vitro, the lethal dose and histopathological analysis showed the low toxicity of these formulations (all of them on Category 4 of the Globally Harmonized System of Classification and Labelling of Chemicals) and minor damage observed on analyzed organs. The results provide an additional example of the rational design of safety nanomaterials with antitumor potency and urge further experiments to complete the preclinical studies for these AgNP formulations.

1. Introduction

The urgent need to find new effective and selective antitumor agents has found in nanotechnology a niche of opportunity and a growing field of research [1,2,3]. In this field, silver nanoparticles have been one of the most studied systems [4,5,6,7]. It has been identified that the physicochemical properties that modulate the antitumor activity of AgNPs are size, surface charge, and coating [2,8,9,10]. Many works have studied the effect of coating agent on selective cytotoxicity, identifying that the more stable the binding of the metallic surface with the coating agent, the lower its toxicity [8,11,12,13,14]. Polyvinylpyrrolidone (PVP) is one of the most used polymers to produce stable and effective AgNPs with remarkable antitumor effects [15,16,17,18]. However, we recently showed that the coating agent selection is not the only thing you need to worry about. The metallic content/coating agent ratio plays a significant role in the cytotoxic and genotoxic response of AgNPs [18,19,20,21].
Recently, many research articles proposed a minimal or negligible contribution of released silver ions to cytotoxicity and found that stable AgNP systems are primarily responsible for ROS overproduction within the exposed cells, which, in turn, trigger cell death pathways [19,20,22,23]. In the search for new treatment alternatives, during the last years, our research group has worked with a completely characterized PVP-AgNPs formulation, which exhibits in vitro [24] and in vivo [25] antimicrobial activity, virucidal effects [26,27,28], antiproliferative and antitumor activity [17,18], antiparasitic potential [29,30,31], immunomodulatory capacity [32,33], and others. We found that the amount of released Ag+ ions after 24 h incubation in the RPMI medium is lower than 1%. The [Metal]/[Coating agent] ratio used to synthesize Argovit® provides this formulation with higher stability, responsible for the low Ag+ release [19]. The aforementioned substantially contributes to Argovit® formulation specificity against pathogens and malignant cells with neither cytotoxic nor genotoxic damage on healthy cells [19,20]. By using another coating agent, in this case protein, but preserving the [Ag]/[coating agent] ratio used in the previous formulation, we found that the effectiveness as an antitumor and antiparasitic agent with high selectivity and little toxicity for BALB mice/c is similar [21].
Therefore, to confirm the role played by the [Ag]/[PVP] ratio on the antitumor activity, cytotoxic selectivity, and low toxicity, we studied five AgNP formulations with [Ag]/[PVP] ratios within a specific range. The cytotoxic activity of the AgNP formulations was evaluated against human colon tumor HCT-15 cells. Their selectivity was determined by exposing BALB/c mice primary cell cultures of the aorta, heart, liver, kidney, and spleen to different concentrations of the studied formulations. We assessed their median lethal dose (LD50) in BALB/c mice and performed histopathological analysis. Our results show that independently of the PVP employed, the amount of PVP is a crucial factor for the antitumor and wide therapeutic index (TI) of the AgNP formulations. All of them show significant cytotoxicity on human colon tumor cells triggered by ROS overproduction in mitochondria, promote a differential-cytotoxic effect on the tumor and non-transformed cells, and possess a wide therapeutic index with an LD50 that corresponds to Group 4 of the GSH classification. These findings open new opportunities for selective and safe nano-material formulation development for biomedical applications.

2. Methodology

2.1. AgNP Formulations

Five different AgNP formulations were kindly donated by the Scientific and Production Center Vector-Vita Ltd.® (Novosibirsk, Russia). PVP-AgNP formulations are stable water suspensions with an overall concentration of 200 mg/mL. From here on, the formulations are labeled as AgNP1, AgNP2, AgNP3, AgNP4, and AgNP5. According to the manufacturer, differences between each AgNP formulation relies on the PVP used as coating agent or the synthesis conditions as follows: AgNP1: PVP K-15; AgNP2: PVP K-17; AgNP3: PVP K-17 with higher radiation potency used for the synthesis; AgNP4: PVP K-30, and AgNP5: PVP 12.6 ± 2.7 KDa. The synthetic procedures to obtain AgNP formulations are enclosed in the patents RU 2,602,534 C2 [34] and RU 2,602,741 C2 [35]. Molecular masses of PVP K-15, K-17, and K-30 PVP (Boai NKY Pharmaceuticals Ltd., Jiaozuo, China) are 8000–12,000 kDa, 10,000–16,000 kDa, and 45,0000–58,000 kDa, respectively. Based on the AgNP stock solution silver content, working solutions with final concentrations of 5.5 µM, 55.6 µM, 556 µM, and 5.5 mM were prepared with injectable water by serial dilutions. From here on, the concentrations used in this work indicate the metallic silver contained in the AgNP formulations.

2.2. Characterization

The morphology of the nanoparticles was analyzed by High Resolution Transmission Electron Microscopy (HR-TEM) using a JEM-2010 (JEOL©). AgNP average diameter (ØAg) and size distribution analysis was determined from TEM micrographs (n = 150) using ImageJ Software [36]. Zeta potential (ζ) and hydrodynamic diameter (Øhydro) were determined by dynamic light scattering (DLS) using a Zetasizer Nano Ns DTS 1060 (Malvern Instruments®). Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) measurements were performed with a DSC/TGA thermal analysis system (SDT Q600, Newtown, PA, USA) under argon atmosphere from 30 to 750 °C at a rate of 10 °C min−1. Moreover, AgNP dilutions were used to determine plasmon resonance by UV/Vis spectroscopy using a JENWAY 6705 spectrophotometer (Cole-Parmer©).

2.3. HCT-15 Cell Culture

HCT-15 human colorectal adenocarcinoma cell line was purchased from the American Type Culture Collection (ATCC® CCL-225™, Manassas, VA, USA). HCT-15 cells were cultured in Petri dishes containing RPMI 1640 medium (Biowest©) supplemented with 10% fetal bovine serum (FBS; Biowest© S1650, Mexico City, Mexico) and 0.01% antibiotic-antimycotic (Biowest© L0010, streptomycin and penicillin G; Nuaillé, Maine-et-Loire, France). Cells were incubated at 37 °C in a 5% CO2 humidified atmosphere. The culture medium was refreshed every 2 days and cells were passaged at 80% confluency.
Cell viability was determined by seeding 20,000 cells/well in 96-well plates with 190 μL of supplemented culture media and exposed for 24 h to 10 µL of each AgNP formulation at final concentrations of 5.5 µM, 55.6 µM, 556 µM, and 5.5 mM. Treatments were added at the same time as cell seeding. Three independent experiments were performed by triplicate for each treatment. Untreated cells were used as negative control administered with 10 μL of complete culture medium. The reported IC50 for carboplatin (190 µM) [37], one of the first-line chemotherapeutic agents for human colon tumor treatment, was used as a positive control. Plates were incubated for 24 h at 37 °C in a 5% CO2 humidified atmosphere. Cell viability was determined using Vybrant™ CFDA SE cell tracer kit (Thermo Fisher Scientific, Waltham, MA, USA) by flow cytometry (Attune NxT flow cytometer, Thermo Fisher Scientific, Waltham, MA, USA).

2.4. Cell Death Modality

Cell death modality induced by exposure to AgNPs and carboplatin was determined using the Dead Cell Apoptosis Kit with Alexa Fluor® 488 Annexin V (AV) and propidium iodide (PI) (Thermo Fisher, Waltham, MA, USA). After 24 h of incubation with the corresponding cytotoxic agent, the cells were harvested and washed with cold PBS and then resuspended in kit-provided binding buffer. The cells were then incubated with 5 μL of AV and 1 μL of PI solution at room temperature for 15 min. After incubation, cells were analyzed in the Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham, MA, USA). At least 10,000 events/experiment were recorded with the BL1 channel for AV detection and VL3 for PI detection. Cells treated with hydrogen peroxide (H2O2) were considered as an apoptosis-positive control (positive for Annexin V; AV+); cells treated to break osmotic pressure were considered as a necrosis positive control (positive for propidium iodide; PI+).

2.5. Mitochondrial ROS Production

The mitochondrial superoxide (O2−) production was assessed using MitoSOX Red mitochondrial superoxide indicator (Invitrogen™, Waltham, MA, USA) by flow cytometry. Cells treated with H2O2 were employed as a positive control. After the exposure to AgNPs, 2 μL of MitoSOX reagent solution were added to each experiment and incubated for 10 min in the dark. Afterward, cells were analyzed in the Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham, MA, USA). At least 10,000 events/experiment were recorded using the VL4 channel.

2.6. Primary Mouse Cell Cultures

Primary mouse cultures were chosen to evaluate the cytotoxic effect of AgNP formulations in non-tumorigenic cells. Primary mouse cultures of aorta, heart, liver, kidney, and spleen were used in this work. For the latter, the viability of lymphocytes and monocytes was determined. The experimental procedure was performed with the approval of the Ethical Committee of the Autonomous University of Baja California (001/2018), and following the NOM-062-ZOO-1999. Briefly, BALB/c mice were euthanized by cervical dislocation and dissected. The cells were isolated from the organs by mechanical maceration, and tissue fragments were washed with phosphate buffer solution (PBS). After that, cells were centrifuged for 10 min at 2500 rpm. The supernatant was removed, and cells were washed with 100 μL of saturated saline solution followed by 900 μL of injectable water for erythrocyte lysis. Afterward, cells were washed three times and seeded in Petri dishes with RPMI 1640 culture medium supplemented with 10% v/v of fetal bovine serum (FBS, Biowest S1650, Mexico City, Mexico). Cells were incubated at 37 °C for 24 h. The cytotoxic effect was assessed by exposing the cells to 5.5 µM, 55.6 µM, 556 µM and 5.5 mM of AgNP formulations for 24 h. In the case of the spleen, the primary culture was incubated at 37 °C for at least 2 h to separate spleen monocytes from lymphocytes. After that time, monocytes adhere at the bottom of the dish allowing the collection of suspended lymphocytes. The lymphocytes collected were placed in a different container with fresh media. The same concentration ranges and exposure time used for the other primary cultures was employed to evaluate the cytotoxic effect on isolated lymphocytes and monocytes. After the incubation period, the cell type viability was determined independently by flow cytometry, based on cell size and cytoplasmic granularity. At least 10,000 events were analyzed using the Attune™ NxT flow cytometer (Thermo Fisher Scientific, Waltham, MA, USA).

2.7. Lethal Dose (LD50)

The lethal dose (LD50) of the five formulations was determined through the limit test according to OECD Guideline 420 for Acute Oral Toxicity Assay [38] using eight-week-old BALB/c mice with an average body weight range of 20–24 g. The experimental protocol was approved by the Ethical Committee of the Autonomous University of Baja California (001/2018), Mexico. Mice were assigned to polycarbonate cages and kept at 25 °C, 60% humidity, 12/12-h light-dark cycle with food and water ad libitum. Mice were orally administered 0.4 mL of the corresponding AgNPs every 2 h for a total of 12 doses in a period of 24 h. The total amount of silver administered to each mouse was in the range of 1067–1806 mg of metallic silver/Kg of body weight. Clinical signs, including skin and fur appearance, eyes, membranes, conduct, respiratory pattern, the presence of nausea, vomiting, diarrhea, tremors, convulsions, salivation, lethargy, sleep, coma, and death, were carefully registered throughout the experiment. Liver, kidney, spleen, lung, intestine, heart, and brain were removed and placed in 10% formaldehyde for histopathological evaluation.

2.8. Histopathology

The histopathologic analysis was performed as recommended by the OCDE Guide 420. Three to five-micrometer sections of paraffin-embedded organs stained with Hematoxylin and eosin (H&E) were used to identify possible tissue injuries.

2.9. Statistical Analysis

The obtained data were analyzed using GraphPad Prism version 9.0 software. The results were expressed as mean ± standard deviation of three experiments. Data were evaluated by two-way analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. The results were considered statistically significant when p ˂ 0.05.

3. Results

AgNPs Characterization

AgNP formulations were analyzed by TEM, UV-vis, DLS, and TGA. TEM micrographs revealed a spheroidal morphology of the metallic silver cores, although triangular shapes (possibly pyramidal prisms) were also observed (Figure 1). The average diameters (ØAg) of the metallic particles were 16.4 ± 8.0 nm, 25.4 ± 13.2 nm, 19.0 ± 9.3 nm, 16.4 ± 8.1 nm, 30.6 ± 23.2 nm for AgNP1 to AgNP5, respectively. Furthermore, size distributions showed that AgNP formulations were polydisperse with predominant diameters in the range of 10–20 nm.
The UV-vis spectra of the five AgNPs formulations were acquired at different concentrations, as shown in Figure 2a. AgNP1 to AgNP4 showed an absorption peak between 400–415 nm. No defined peaks were observed for AgNP5, but a plateau-like distribution was seen. This absorption, common among formulations, corresponds to the characteristic surface plasmon resonance of nanometric silver [19]. Furthermore, AgNP2 and AgNP4 formulations showed a second peak of lower intensity. The apparition of two or more absorption peaks can be due to the presence of irregular particles (non-spherical) within the AgNP formulations, which results in the widening of the peak [39].
The hydrodynamic diameter (Øhydro) and zeta potential (ζ) of the AgNP formulations are summarized in Table 1. A wide range of Øhydro was found; AgNP1 and AgNP4 showed the larger size with 448 and 483 nm, AgNP5 has a diameter of 121 nm, while diameters for AgNP2 and AgNP3 are 90 and 43 nm, respectively. The ζ potential values were within the range −5 to +5 mV, where the higher values (absolute values) correspond to the minor Øhydro registered. As the ζ values get close to zero, a higher Øhydro was found (Table 1).
The TGA/DSC analysis show the water, polymer, and metallic content for each formulation. The metallic content was in the range 1.1–1.3%, the protein coating was 19.6–24.5%, and water was 74.2–79.2% w/w. Those formulations with the highest coating protein content, AgNP2 and AgNP3, also showed the lower Øhydro values and the higher ζ potential values. These results highlight the role played by the coating on the physicochemical properties of these AgNP formulations.

4. Cell Viability

4.1. Antitumor Activity

The cytotoxic effect of AgNPs on human colon tumor cells (HCT-15) was studied after 24 h exposure to concentrations from 5.5 µM to 5.5 mM of metallic silver contained in AgNP formulations (Figure 3). The five AgNP formulations evaluated in this work showed a similar cytotoxic effect on HCT-15 cultures to carboplatin (Figure 3a). From the lowest concentration of AgNP formulations assessed (5.5 µM), the observed cell viability decrease showed no significant statistical differences with carboplatin results, except for AgNP1, which reached the above-described effect at 556 µM. Formulations AgNP2–AgNP5 showed a decrease in their cytotoxicity at 5.5 mM, probably produced by nanoparticle aggregation (Figure 3a). In our experimental conditions, the reported IC50 for carboplatin on HCT-15 produced a cell viability decrease of 42–44% (Figure 3).
Interestingly, AgNP1 at concentrations from 5.5–556 µM showed a concentration-dependent increase in positive apoptotic events (Figure 3b). The other AgNP formulations always presented apoptosis within the range of 5–35%, regardless of the assessed concentration (Figure 3b). For necrosis, positive events were within the range of 2.5–7%, except for AgNP1, which was 9% at a concentration of 5.5 mM (Figure 3c).
Regardless of the concentration, all the formulations induced a 40% increase of mitochondrial superoxide in the cells exposed to AgNPs (Figure 3d). This mitochondrial ROS-overproduction could be the trigger of cell death pathways identified on HCT-15 cells (Figure 3b,c) exposed to AgNP1–AgNP5.

4.2. Primary Mouse Cultures

Cytotoxic selectivity of AgNP formulations AgNP1–AgNP5 was determined by exposing primary cultures of mouse aorta, bone marrow, heart, kidney, liver, and spleen to 5.5 µM, 55.6 µM, 556 µM, and 5.5 mM of the corresponding AgNP formulations. Similar to tumor cell cultures, the cell viability responses of each mice primary culture exposed to AgNPs are practically the same regardless of the concentration or formulation of AgNP assessed. The lowest effect on cell viability decrease was observed on the aorta cultures, where only a 5% decrease compared with the control was registered (Figure 4a). Bone marrow and heart primary cultures exposed to AgNPs presented a similar trend with a cell viability decrease of 5–10% (Figure 4b,c). Kidney and liver primary cultures showed a 15–20% diminishing cell viability after AgNP exposure (Figure 4d,e). Spleen cultures exposed to the highest concentration (5.5 mM) of the AgNP formulations assessed showed the most significant cell viability diminishing of all the series, a 30% decrease compared with the control (Figure 4f). Spleen lymphocytes exhibited a narrow reduction in cell viability, from 5–7% compared with the control (untreated cells, Figure 4h). On the other hand, spleen monocytes showed a meaningful decrease after exposure to 5.5 µM–556 µM of AgNPs (Figure 4g). Spleen monocytes’ cell viability abruptly dropped up to 46% when increasing concentration to 5.5 mM. The distinct difference in the cytotoxic effect between spleen lymphocytes and monocytes could be associated with their phagocytic capability.

4.3. Determination of Lethal Dose

The lethal dose of five AgNP formulations studied in this work were determined on BALB/c mice through a limit test. To avoid further suffering of experimental animals, we euthanized the surviving mice and concluded the study before 12 h of observation. All mice showed toxicity signs during the limit tests; however, the administered dose of silver contained on the AgNP formulation is considerably high, as shown in Table 2. The median lethal doses determined for each formulation are compiled in Table 2.

4.4. Histological Analysis

The histological analysis of organs from mice exposed to AgNP formulations during the limit test showed minimal toxic effects after the observational period. Table 3 compiles the most relevant findings in the lung, kidney, heart, spleen, liver, esophagus, stomach, and intestine; however, it is imperative to note that described damage is only observed in some exposed mice. In general, images show the accumulation of dark non-cellular material (probably AgNPs) in different tissues’ interstitium. The most evident accumulation is observed in the gastrointestinal system (esophagus (Figure 5g), the gastroesophageal union (Figure 5h), stomach (Figure 5i), small intestine (Figure 5k,l), and the liver (Figure 5f)). The observed accumulation on these organs could be associated with the administration route. Despite the accumulation, no tissue damage was observed within 12 h of the acute toxicity study. These results agree with those observed in the in vitro cytotoxic assays using primary mouse cultures. AgNP formulations showed the most significant cytotoxic effects on the organ cells that showed the highest accumulation on the histological observations.

5. Discussion

In this study, we evaluated the cytotoxicity of five new AgNP formulations against human colon tumor HCT-15 cells. The AgNP formulations have a [Ag]/[PVP] ratio within the range [1.19–1.32% w/w]/[19.6–24.5% w/w] as shown in Table 1 (or [5–5.7% w/w]/[94.3–95% w/w] if the dry formulation is considered). The shape of the nanoparticles is predominantly spherical with a size distribution within the range of 5–80 nm (Table 1). Interestingly, both formulations with lowest PVP content, AgNP1 and AgNP4, exhibited a higher hydrodynamic diameter and a lower surface charge (Table 1). These results agree with those obtained by Kyrychenko and co-workers with molecular dynamics studies. They found that an increase in the amount and the length of PVP oligomers increased the coating coverage and avoided AgNP self-aggregation [40].
Several AgNPs that use PVP as a coating agent minimized cytotoxic and genotoxic effects [8,41,42], but only significantly increasing the amount of PVP leads to an absence of toxicity, as we previously reported in several in vitro and in vivo models [18,19,20,33]. Several AgNPs promote ROS overproduction, identified as one of the apoptosis triggers in tumor cells exposed to them. However, many exhibited genotoxic damage even when PVP was used as the coating agent [11,15,43,44,45,46].
In the case of AgNP formulations evaluated in human colon tumor cells, most of them present their cytotoxic effect by ROS overproduction, which leads to apoptosis induction; however, limited information about coating agent or formulation stability is available [47,48,49,50,51,52,53,54,55,56,57]. The results of this work agree with the general trend, all the formulations assessed promote mitochondrial ROS overproduction (Figure 3d) and trigger apoptosis (Figure 3b) as the major cell death pathway. AgNP’s mitochondrial ROS overproduction could be associated with is capacity to modulate the expression of NOX4, the gene that encodes the enzyme NADPH 4 oxidase in humans. Lee and co-workers found that human colon tumor cells HCT116 exposed to AgNPs show mitochondrial disfunction (MD) and endoplasmic reticulum (ER) stress associated with NOX4 expression. However, induced damage was significantly inhibited by pretreatment with diphenyleneiodonium (DPI) or 4-phenyl butyric acid (4-PBA), specific inhibitors of NADPH 4 oxidase and ER stress, respectively [58].
The necrosis observed (Figure 3c) could be associated with the high cytotoxic potency of the AgNP formulations, which in general are more than 30 times more potent than carboplatin. Cell viability observed in cells exposed to 190 µM of carboplatin is similar to that observed in cells exposed to 5.5 µM of AgNP2–AgNP5. Necrosis could be decreased or avoided with frequent administration of a lower concentration. The cytotoxicity of the five formulations exhibits a non-concentration dependent effect. This behavior was already observed in human colorectal cancer (DLD-1 and HT29) [17] and murine melanoma (B16F10) [18] exposed to a PVP-AgNP formulation with a similar composition (Ag 1.2% w/w and PVP 18.8% w/w). Interestingly, the aforementioned formulation induces a concentration-dependent cytotoxic activity on human breast cancer (MDA-MB-231 and MCF-7), cervix (HeLa), prostate (DU-145), and lung (H1299 and H1437). The above shows that formulations with this type of [metallic content]/[coating agent] ratio present selectivity in cytotoxic activity according to the cancer cell type.
The selective cytotoxic effect was also observed in primary mouse cultures. Liver, kidney, and spleen cells are most sensitive to AgNPs, as shown in Figure 4. The higher sensitivity of these cells compared to the aorta, bone marrow, and heart cultures are related to their enhanced phagocytic capabilities to incorporate AgNPs, also favored by the tendency of AgNPs to accumulate in the liver regardless of the administration route [7,59,60,61,62,63]. Enhanced cytotoxicity on phagocytic cells was also observed on spleen cultures, where a pronounced cell viability decrease was observed on monocytes without significant modification of lymphocyte viability (Figure 4g,h). Despite the cytotoxic effect registered in vitro on liver, kidney, and spleen cultures, no evidence of tissue damage was observed on the histological analysis after oral administration (Figure 5) used to determine the medium lethal dose (LD50) through a limit test.
Histological analysis showed the accumulation of AgNPs, mainly in the gastrointestinal system. Interestingly, even with the significant accumulation in the tissue, minimal damage was observed. The lack of damage could be attributed to the considerable amount of coating agent, enhanced by its high clearance rate, as we have shown in previous works [18,21,64,65,66,67]. These features definitely contribute to the wide therapeutic window found for the five formulations assessed in this work. They all present an LD50 value within the range of 1067–1548 mg of silver/Kg of mouse body weight. The LD50 values found place the five formulations in category 4 of the GSH classification, the same category as carboplatin (343 mg/Kg by oral administration) [68]. Considering AgNPs and carboplatin cytotoxic effects on HCT-15 and their LD50 values, a rough value of therapeutic index (TI) can be obtained by LD50/IC50, resulting in TI values within the range of 179–304 for AgNP formulations and 4.86 for carboplatin. In summary, the results obtained in this work show that a high amount of PVP used as a coating agent to obtain AgNP formulations, independently of polymer length, generates a wide therapeutic window for selective cytotoxic agents to BALB/c mice compared to the first-line chemotherapeutic agent, carboplatin.

6. Conclusions

In this work, we present the complete characterization of five PVP-AgNP formulations with composition within the range Ag: 1.14–1.32% w/w, PVP: 19.6–24.5%, and H2O: 74.2–79.2%. The AgNPs have spherical shapes with an average size range of 16–30 nm determined by TEM. All formulations exhibit a potency 34.5 times higher than carboplatin against human colorectal HCT-15 cells, except for AgNP1, which presented twice the cytotoxic potency of the platin metallodrug. The studied formulations show high cytotoxic selectivity and enhanced sensitivity for phagocytic cells. Despite the in vitro cell viability decrease found, a remarkably wide therapeutic window on BALB/c mice was observed. Histopathological analysis showed the accumulation of non-cellular material, mainly in the gastrointestinal system, without significant damage to exposed tissue. The selective cytotoxic effect and minimal damage observed on the mice tissue after oral administration of the five AgNP formulations are associated with the [metal]/[coating agent] ratio used to produce them. This feature placed all of the formulations at Category 4 of the Globally Harmonized System of Classification and Labelling of Chemicals. Our results provide an additional example of the rational design of safe nanomaterials with selective cytotoxic potency.

Author Contributions

Conceptualization, J.C.G.-R. and Y.T.-M.; Data curation, O.U.C.-R., L.M.V.-S., A.B.-S., J.A.R.-A. and P.A.M.-M.; Formal analysis, O.U.C.-R., L.M.V.-S., A.B.-S., J.A.R.-A., P.A.M.-M., J.C.G.-R. and Y.T.-M.; Funding acquisition, J.C.G.-R., N.B., A.P. and Y.T.-M.; Investigation, O.U.C.-R., L.M.V.-S., A.B.-S., P.A.M.-M., J.C.G.-R. and Y.T.-M.; Methodology, O.U.C.-R., L.M.V.-S., A.B.-S., J.A.R.-A., P.A.M.-M. and Y.T.-M.; Project administration, J.C.G.-R. and Y.T.-M.; Resources, N.B., A.P. and Y.T.-M.; Software, J.C.G.-R.; Supervision, J.C.G.-R., N.B. and Y.T.-M.; Validation, L.M.V.-S., A.B.-S., J.A.R.-A. and P.A.M.-M.; Visualization, O.U.C.-R., L.M.V.-S., A.B.-S., J.A.R.-A., P.A.M.-M. and J.C.G.-R.; Writing—original draft, O.U.C.-R., A.B.-S., J.C.G.-R. and Y.T.-M.; Writing—review & editing, L.M.V.-S., P.A.M.-M., J.C.G.-R., N.B. and Y.T.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by UABC SICASPI -351/2420, UABC SICASPI-439/2560, UABC SICASPI 439-2577, SEP PRODEP UABC-PTC-819, SEP PRODEP UABC-PTC-869, and Tomsk Polytechnic University Development Program “Priority 2030”. The APC was funded by Universidad Nacional Autónoma de México.

Institutional Review Board Statement

The Ethical Committee of the Autonomous University of Baja California approved the experimental protocol 001/2018; 25 May 2018.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors acknowledge SEP-PRODEP and Red Internacional de Bionanotecnología con Impacto en Nanomedicina, Alimentación y Bioseguridad del CONACyT for the financial support. A.B.S. and J.A.R.A. thank CONACyT for the scholarship granted to participate in Programa de Maestría y Doctorado en Ciencias e Ingeniería from UABC.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Montaseri, H.; Kruger, C.A.; Abrahamse, H. Inorganic nanoparticles applied for active targeted photodynamic therapy of breast cancer. Pharmaceutics 2021, 13, 296. [Google Scholar] [CrossRef] [PubMed]
  2. Morais, M.; Teixeira, A.L.; Dias, F.; Machado, V.; Medeiros, R.; Prior, J.A.V. Cytotoxic effect of silver nanoparticles synthesized by green methods in cancer. J. Med. Chem. 2020, 63, 14308–14335. [Google Scholar] [CrossRef] [PubMed]
  3. Gupta, N.; Malviya, R. Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer. Biochim. Biophys. Acta Rev. Cancer 2021, 1875, 188532. [Google Scholar] [CrossRef]
  4. Xu, L.; Wang, Y.Y.; Huang, J.; Chen, C.Y.; Wang, Z.X.; Xie, H. Silver nanoparticles: Synthesis, medical applications and biosafety. Theranostics 2020, 10, 8996–9031. [Google Scholar] [CrossRef] [PubMed]
  5. Li, Y.; Chang, Y.; Lian, X.; Zhou, L.; Yu, Z.; Wang, H.; An, F. Silver nanoparticles for enhanced cancer theranostics: In vitro and in vivo perspectives. J. Biomed. Nanotechnol. 2018, 14, 1515–1542. [Google Scholar] [CrossRef]
  6. Akter, M.; Sikder, M.T.; Rahman, M.M.; Ullah, A.K.M.A.; Hossain, K.F.B.; Banik, S.; Hosokawa, T.; Saito, T.; Kurasaki, M. A systematic review on silver nanoparticles-induced cytotoxicity: Physicochemical properties and perspectives. J. Adv. Res. 2018, 9, 1–16. [Google Scholar] [CrossRef]
  7. Liao, C.; Li, Y.; Tjong, S.C. Bactericidal and cytotoxic properties of silver nanoparticles. Int. J. Mol. Sci. 2019, 20, 449. [Google Scholar] [CrossRef] [Green Version]
  8. Nallanthighal, S.; Chan, C.; Bharali, D.J.; Mousa, S.A.; Vásquez, E.; Reliene, R. Particle coatings but not silver ions mediate genotoxicity of ingested silver nanoparticles in a mouse model. NanoImpact 2017, 5, 92–100. [Google Scholar] [CrossRef] [Green Version]
  9. Recordati, C.; de Maglie, M.; Bianchessi, S.; Argentiere, S.; Cella, C.; Mattiello, S.; Cubadda, F.; Aureli, F.; d’Amato, M.; Raggi, A.; et al. Tissue distribution and acute toxicity of silver after single intravenous administration in mice: Nano-specific and size-dependent effects. Part. Fibre Toxicol. 2016, 13, 1–17. [Google Scholar] [CrossRef] [Green Version]
  10. Zielińska, A.; Costa, B.; Ferreira, M.V.; Miguéis, D.; Louros, J.M.S.; Durazzo, A.; Lucarini, M.; Eder, P.; Chaud, M.V.; Morsink, M.; et al. Nanotoxicology and nanosafety: Safety-by-design and testing at a glance. Int. J. Environ. Res. Public Health 2020, 17, 4657. [Google Scholar] [CrossRef]
  11. Nymark, P.; Catalán, J.; Suhonen, S.; Järventaus, H.; Birkedal, R.; Clausen, P.A.; Jensen, K.A.; Vippola, M.; Savolainen, K.; Norppa, H. Genotoxicity of polyvinylpyrrolidone-coated silver nanoparticles in BEAS 2B cells. Toxicology 2013, 313, 38–48. [Google Scholar] [CrossRef]
  12. Rodriguez-Garraus, A.; Azqueta, A.; Vettorazzi, A.; de Cerain, A.L. Genotoxicity of silver nanoparticles. Nanomaterials 2020, 10, 251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Báez, J.E. Cómo obtener un polímero degradable en el laboratorio: Síntesis de la poli (d, l -lactida) y caracterización por RMN 1H. Educ. Química 2010, 21, 170–177. [Google Scholar] [CrossRef]
  14. Vuković, B.; Milić, M.; Dobrošević, B.; Milić, M.; Ilić, K.; Pavičić, I.; Šerić, V.; Vrček, I.V. Surface stabilization affects toxicity of silver nanoparticles in human peripheral blood mononuclear cells. Nanomaterials 2020, 10, 1390. [Google Scholar] [CrossRef] [PubMed]
  15. Foldbjerg, R.; Jiang, X.; Micləuş, T.; Chen, C.; Autrup, H.; Beer, C. Silver nanoparticles—Wolves in sheep’s clothing? Toxicol. Res. 2015, 4, 563–575. [Google Scholar] [CrossRef]
  16. Guo, D.; Zhu, L.; Huang, Z.; Zhou, H.; Ge, Y.; Ma, W.; Wu, J.; Zhang, X.; Zhou, X.; Zhang, Y.; et al. Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions. Biomaterials 2013, 34, 7884–7894. [Google Scholar] [CrossRef]
  17. Juarez-Moreno, K.; Gonzalez, E.; Girón-Vazquez, N.; Chávez-Santoscoy, R.; Mota-Morales, J.; Perez-Mozqueda, L.; Garcia-Garcia, M.; Pestryakov, A.; Bogdanchikova, N. Comparison of cytotoxicity and genotoxicity effects of silver nanoparticles on human cervix and breast cancer cell lines. Hum. Exp. Toxicol. 2017, 36, 931–948. [Google Scholar] [CrossRef]
  18. Valenzuela-Salas, L.M.; Girón-Vázquez, N.G.; García-Ramos, J.C.; Torres-Bugarín, O.; Gómez, C.; Pestryakov, A.; Villarreal-Gómez, L.J.; Toledano-Magaña, Y.; Bogdanchikova, N. Antiproliferative and antitumour effect of nongenotoxic silver nanoparticles on melanoma models. Oxid. Med. Cell. Longev. 2019, 2019, 1–12. [Google Scholar] [CrossRef]
  19. Ruiz-Ruiz, B.; Arellano-García, M.E.; Radilla-Chávez, P.; Salas-Vargas, D.S.; Toledano-Magaña, Y.; Casillas-Figueroa, F.; Luna Vazquez-Gomez, R.; Pestryakov, A.; García-Ramos, J.C.; Bogdanchikova, N. Cytokinesis-block micronucleus assay using human lymphocytes as a sensitive tool for cytotoxicity/genotoxicity evaluation of AgNPs. ACS Omega 2020. [Google Scholar] [CrossRef] [PubMed]
  20. Casillas-Figueroa, F.; Arellano-García, M.E.; Leyva-Aguilera, C.; Ruíz-Ruíz, B.; Vázquez-Gómez, R.L.; Radilla-Chávez, P.; Chávez-Santoscoy, R.A.; Pestryakov, A.; Toledano-Magaña, Y.; García-Ramos, J.C.; et al. ArgovitTM silver nanoparticles effects on allium cepa: Plant growth promotion without cyto genotoxic damage. Nanomaterials 2020, 10, 1386. [Google Scholar] [CrossRef]
  21. Valenzuela-Salas, L.M.; Blanco-Salazar, A.; Perrusquía-Hernández, J.D.; Nequiz-Avendaño, M.; Mier-Maldonado, P.A.; Ruiz-Ruiz, B.; Campos-Gallegos, V.; Arellano-García, M.E.; García-Ramos, J.C.; Pestryakov, A.; et al. New protein-coated silver nanoparticles: Characterization, antitumor and amoebicidal activity, antiproliferative selectivity, genotoxicity, and biocompatibility evaluation. Pharmaceutics 2021, 13, 65. [Google Scholar] [CrossRef] [PubMed]
  22. Ivask, A.; Voelcker, N.H.; Seabrook, S.A.; Hor, M.; Kirby, J.K.; Fenech, M.; Davis, T.P.; Ke, P.C. DNA melting and genotoxicity induced by silver nanoparticles and graphene. Chem. Res. Toxicol. 2015, 28, 1023–1035. [Google Scholar] [CrossRef] [PubMed]
  23. Gomathi, A.C.; Xavier Rajarathinam, S.R.; Mohammed Sadiq, A.; Rajeshkumar, S. Anticancer activity of silver nanoparticles synthesized using aqueous fruit shell extract of Tamarindus indica on MCF-7 human breast cancer cell line. J. Drug Deliv. Sci. Technol. 2020, 55, 101376. [Google Scholar] [CrossRef]
  24. Vazquez-Muñoz, R.; Bogdanchikova, N.; Huerta-Saquero, A. Beyond the nanomaterials approach: Influence of culture conditions on the stability and antimicrobial activity of silver nanoparticles. ACS Omega 2020. [Google Scholar] [CrossRef] [PubMed]
  25. Uraskulova, B.B.; Gyusan, A.O. The clinical and bacteriological study of the effectiveness of the application of silver nanoparticle for the treatment of tuberculosis. Vestn. Otorinolaringol. 2017, 82, 54–57. [Google Scholar] [CrossRef] [PubMed]
  26. Romo-Quiñonez, C.R.; Álvarez-Sánchez, A.R.; Álvarez-Ruiz, P.; Chávez-Sánchez, M.C.; Bogdanchikova, N.; Pestryakov, A.; Mejia-Ruiz, C.H. Evaluation of a new Argovit as an antiviral agent included in feed to protect the shrimp Litopenaeus vannamei against white spot syndrome virus infection. PeerJ 2020, 2020, 1–22. [Google Scholar] [CrossRef] [Green Version]
  27. Glotov, A.G.; Glotova, T.I.; Sergeev, A.A.; Belkina, T.V.; Sergeev, A.N. Antiviral activity of different drugs in vitro against viruses of bovine infectious rhinotracheitis and bovine diarrhea. Vopr. Virusol. 2004, 49, 43–46. [Google Scholar]
  28. Glotov, A.G.; Glotova, T.I.; Sergeev, A.A.; Sergeev, A.N. Study of antiviral activity of different drugs against bovine herpes and pestivirus. Antibiot. ChemotHerapy 2004, 49, 6–9. [Google Scholar]
  29. Fuentes-Valencia, M.A.; Fajer-Ávila, E.J.; Chávez-Sánchez, M.C.; Martínez-Palacios, C.A.; Martínez-Chávez, C.C.; Junqueira-Machado, G.; Lara, H.H.; Raggi, L.; Gómez-Gil, B.; Pestryakov, A.A.; et al. Silver nanoparticles are lethal to the ciliate model Tetrahymena and safe to the pike silverside Chirostoma estor. Exp. Parasitol. 2020, 209. [Google Scholar] [CrossRef]
  30. Bravo-Guerra, C.; Cáceres-Martínez, J.; Vásquez-Yeomans, R.; Pestryakov, A.; Bogdanchikova, N. Lethal effects of silver nanoparticles on Perkinsus marinus, a protozoan oyster parasite. J. Invertebr. Pathol. 2020, 169, 107304. [Google Scholar] [CrossRef]
  31. Pimentel-Acosta, C.A.; Morales-Serna, F.N.; Chávez-Sánchez, M.C.; Lara, H.H.; Pestryakov, A.; Bogdanchikova, N.; Fajer-Ávila, E.J. Efficacy of silver nanoparticles against the adults and eggs of monogenean parasites of fish. Parasitol. Res. 2019, 118, 1741–1749. [Google Scholar] [CrossRef]
  32. Ochoa-Meza, A.R.; Álvarez-Sánchez, A.R.; Romo-Quiñonez, C.R.; Barraza, A.; Magallón-Barajas, F.J.; Chávez-Sánchez, A.; García-Ramos, J.C.; Toledano-Magaña, Y.; Bogdanchikova, N.; Pestryakov, A.; et al. Silver nanoparticles enhance survival of white spot syndrome virus infected Penaeus vannamei shrimps by activation of its immunological system. Fish Shellfish Immunol. 2019, 84, 1083–1089. [Google Scholar] [CrossRef] [PubMed]
  33. Castro-Gamboa, S.; Garcia-Garcia, M.R.; Piñon-Zarate, G.; Rojas-Lemus, M.; Jarquin-Yañez, K.; Angel Herrera-Enriquez, M.; Fortoul, T.I.; Toledano-Magaña, Y.; Garcia-Iglesias, T.; Pestryakov, A.; et al. Toxicity of silver nanoparticles in mouse bone marrow-derived dendritic cells: Implications for phenotype. J. Immunotoxicol. 2019, 16, 1–9. [Google Scholar] [CrossRef]
  34. Burmistrov, V.A.; Burmistrov, A.V.; Burmistrov, I.V.; Burmistrov, A.V.; Pestryakov, A.N.; Odegova, G.V.; Bogdanchikova, N.E. Method of Producing Coloidal Silver Nanoparticles. RU2602534C2, 20 November 2016. [Google Scholar]
  35. Burmistrov, V.A.; Pestryakov, A.N.; Odegova, G.V.; Burmistrov, I.V.; Burmistrov, A.V.; Bogdanchikova, N.E. Method of Producing Water Soluble Composition of Silver Nanoparticles. RU2602741C2, 20 November 2016. [Google Scholar]
  36. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9, 671–675. [Google Scholar] [CrossRef]
  37. Kitada, N.; Takara, K.; Minegaki, T.; Itoh, C.; Tsujimoto, M.; Sakaeda, T.; Yokoyama, T. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother. Pharmacol. 2008, 62, 577–584. [Google Scholar] [CrossRef] [PubMed]
  38. OECD Test No. 420: Acute oral toxicity—Fixed dose procedure. In OECD Guidelines for the Testing of Chemicals; OECD: Paris, France, 2002.
  39. Del Carmen Sánchez-Navarro, M.; Ruiz-Torres, C.A.; Niño-Martínez, N.; Sánchez-Sánchez, R.; Martínez-Castañón, G.A.; DeAlba-Montero, I.; Ruiz, F. Cytotoxic and bactericidal effect of silver nanoparticles obtained by green synthesis method using annona muricata aqueous extract and functionalized with 5-fluorouracil. Bioinorg. Chem. Appl. 2018, 2018. [Google Scholar] [CrossRef] [Green Version]
  40. Kyrychenko, A.; Korsun, O.M.; Gubin, I.I.; Kovalenko, S.M.; Kalugin, O.N. Atomistic simulations of coating of silver nanoparticles with poly(vinylpyrrolidone) oligomers: Effect of oligomer chain length. J. Phys. Chem. C 2015, 119, 7888–7899. [Google Scholar] [CrossRef]
  41. Vecchio, G.; Fenech, M.; Pompa, P.P.; Voelcker, N.H. Lab-on-a-chip-based high-throughput screening of the genotoxicity of engineered nanomaterials. Small 2014, 10, 2721–2734. [Google Scholar] [CrossRef] [PubMed]
  42. Yan, J.; Zhou, T.; Cunningham, C.K.; Chen, T.; Jones, M.Y.; Abbas, M.; Li, Y.; Mei, N.; Guo, X.; Moore, M.M.; et al. Size- and coating-dependent cytotoxicity and genotoxicity of silver nanoparticles evaluated using in vitro standard assays. Nanotoxicology 2016, 10, 1373–1384. [Google Scholar] [CrossRef]
  43. Mao, B.H.; Tsai, J.C.; Chen, C.W.; Yan, S.J.; Wang, Y.J. Mechanisms of silver nanoparticle-induced toxicity and important role of autophagy. Nanotoxicology 2016, 10, 1021–1040. [Google Scholar] [CrossRef]
  44. Foldbjerg, R.; Dang, D.A.; Autrup, H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch. Toxicol. 2011, 85, 743–750. [Google Scholar] [CrossRef]
  45. Ahlberg, S.; Antonopulos, A.; Diendorf, J.; Dringen, R.; Epple, M.; Flöck, R.; Goedecke, W.; Graf, C.; Haberl, N.; Helmlinger, J.; et al. PVP-coated, negatively charged silver nanoparticles: A multi-center study of their physicochemical characteristics, cell culture and in vivo experiments. Beilstein J. Nanotechnol. 2014, 5, 1944–1965. [Google Scholar] [CrossRef]
  46. Wang, X.; Li, T.; Su, X.; Li, J.; Li, W.; Gan, J.; Wu, T.; Kong, L.; Zhang, T.; Tang, M.; et al. Genotoxic effects of silver nanoparticles with/without coating in human liver HepG2 cells and in mice. J. Appl. Toxicol. 2019, 39, 908–918. [Google Scholar] [CrossRef]
  47. Gurunathan, S.; Qasim, M.; Park, C.; Yoo, H.; Kim, J.H.; Hong, K. Cytotoxic potential and molecular pathway analysis of silver nanoparticles in human colon cancer cells HCT116. Int. J. Mol. Sci. 2018, 19, 2269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Miethling-Graff, R.; Rumpker, R.; Richter, M.; Verano-Braga, T.; Kjeldsen, F.; Brewer, J.; Hoyland, J.; Rubahn, H.G.; Erdmann, H. Exposure to silver nanoparticles induces size- and dose-dependent oxidative stress and cytotoxicity in human colon carcinoma cells. Toxicol. Vitr. 2014, 28, 1280–1289. [Google Scholar] [CrossRef] [PubMed]
  49. Ahamed, M.; Karns, M.; Goodson, M.; Rowe, J.; Hussain, S.M.; Schlager, J.J.; Hong, Y. DNA damage response to different surface chemistry of silver nanoparticles in mammalian cells. Toxicol. Appl. Pharmacol. 2008, 233, 404–410. [Google Scholar] [CrossRef]
  50. Jia, M.; Zhang, W.; He, T.; Shu, M.; Deng, J.; Wang, J.; Li, W.; Bai, J.; Lin, Q.; Luo, F.; et al. Evaluation of the genotoxic and oxidative damage potential of silver nanoparticles in human NCM460 and HCT116 cells. Int. J. Mol. Sci. 2020, 21, 1618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Satapathy, S.R.; Mohapatra, P.; Das, D.; Siddharth, S.; Kundu, C.N. The apoptotic effect of plant based nanosilver in colon cancer cells is a p53 dependent process involving ROS and JNK cascade. Pathol. Oncol. Res. 2015, 21, 405–411. [Google Scholar] [CrossRef]
  52. Xiao, H.; Chen, Y.; Alnaggar, M. Silver nanoparticles induce cell death of colon cancer cells through impairing cytoskeleton and membrane nanostructure. Micron 2019, 126, 102750. [Google Scholar] [CrossRef]
  53. Ansari, M.A.; Asiri, S.M.M.; Alzohairy, M.A.; Alomary, M.N.; Almatroudi, A.; Khan, F.A. Biofabricated fatty acids-capped silver nanoparticles as potential antibacterial, antifungal, antibiofilm and anticancer agents. Pharmaceuticals 2021, 14, 139. [Google Scholar] [CrossRef]
  54. Gopinath, P.; Gogoi, S.K.; Sanpui, P.; Paul, A.; Chattopadhyay, A.; Ghosh, S.S. Signaling gene cascade in silver nanoparticle induced apoptosis. Colloid. Surface. B. 2010, 77, 240–245. [Google Scholar] [CrossRef]
  55. González-Ballesteros, N.; Rodríguez-Argüelles, M.C.; Prado-López, S.; Lastra, M.; Grimaldi, M.; Cavazza, A.; Nasi, L.; Salviati, G.; Bigi, F. Macroalgae to nanoparticles: Study of Ulva lactuca L. role in biosynthesis of gold and silver nanoparticles and of their cytotoxicity on colon cancer cell lines. Mater. Sci. Eng. C 2019, 97, 498–509. [Google Scholar] [CrossRef]
  56. Majeed, S.; Aripin, F.H.B.; Shoeb, N.S.B.; Danish, M.; Ibrahim, M.N.M.; Hashim, R. Bioengineered silver nanoparticles capped with bovine serum albumin and its anticancer and apoptotic activity against breast, bone and intestinal colon cancer cell lines. Mater. Sci. Eng. C 2019, 102, 254–263. [Google Scholar] [CrossRef]
  57. Balkrishna, A.; Sharma, V.K.; Das, S.K.; Mishra, N.; Bisht, L.; Joshi, A.; Sharma, N. Characterization and anti-cancerous effect of Putranjiva roxburghii seed extract mediated silver nanoparticles on human colon (HCT-116), pancreatic (PANC-1) and breast (MDA-MB 231) cancer cell lines: A comparative study. Int. J. Nanomed. 2020, 15, 573–585. [Google Scholar] [CrossRef] [Green Version]
  58. Quan, J.-H.; Gao, F.F.; Chu, J.-Q.; Cha, G.-H.; Yuk, J.-M.; Wu, W.; Lee, Y.-H. Silver nanoparticles induce apoptosis via NOX4 -derived mitochondrial reactive oxygen species and endoplasmic reticulum stress in colorectal cancer cells. Nanomedicine 2021. [Google Scholar] [CrossRef]
  59. Elje, E.; Mariussen, E.; Moriones, O.H.; Bastús, N.G.; Puntes, V.; Kohl, Y.; Dusinska, M.; Rundén-Pran, E. Hepato(Geno)toxicity assessment of nanoparticles in a hepg2 liver spheroid model. Nanomaterials 2020, 10, 545. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Vilas-Boas, V.; Vinken, M. Hepatotoxicity induced by nanomaterials: Mechanisms and in vitro models. Arch. Toxicol. 2021, 95, 27–52. [Google Scholar] [CrossRef] [PubMed]
  61. Albrahim, T.; Alonazi, M.A. Role of beetroot (Beta vulgaris) juice on chronic nanotoxicity of silver nanoparticle-induced hepatotoxicity in male rats. Int. J. Nanomed. 2020, 15, 3471–3482. [Google Scholar] [CrossRef] [PubMed]
  62. Mendonça, M.C.P.; Ferreira, L.B.; Rizoli, C.; Batista, Â.G.; Maróstica, M.R., Jr.; da Silva, E.d.N.; Cadore, S.; Durán, N.; da Cruz-Höfling, M.A.; de Jesus, M.B. N-Acetylcysteine reverses silver nanoparticle intoxication in rats. Nanotoxicology 2019, 13, 326–338. [Google Scholar] [CrossRef] [PubMed]
  63. Vandebriel, R.J.; Tonk, E.C.M.; de la Fonteyne-Blankestijn, L.J.; Gremmer, E.R.; Verharen, H.W.; van der Ven, L.T.; van Loveren, H.; de Jong, W.H. Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats. Part. Fibre Toxicol. 2014, 11, 1–9. [Google Scholar] [CrossRef] [Green Version]
  64. Demin, V.A.; Demin, V.F.; Buzulukov, Y.P.; Kashkarov, P.K.; Levin, A.D. Formation of certified reference materials and standard measurement guides for development of traceable measurements of mass fractions and sizes of nanoparticles in different media and biological matrixes on the basis of gamma-ray and optical spectroscopy. Nanotechnol. Russ. 2013, 8, 347–356. [Google Scholar] [CrossRef]
  65. Buzulukov, Y.P.; Arianova, E.A.; Demin, V.F.; Safenkova, I.V.; Gmoshinski, I.V.; Tutelyan, V.A. Bioaccumulation of silver and gold nanoparticles in organs and tissues of rats studied by neutron activation analysis. Biol. Bull. 2014, 41, 255–263. [Google Scholar] [CrossRef]
  66. Melnik, E.A.; Buzulukov, Y.P.; Demin, V.F.A.; Demin, V.F.A.; Gmoshinski, I.V.; Tyshko, N.V.; Tutelyan, V.A. Transfer of silver nanoparticles through the placenta and breast milk during in vivo experiments on rats. Acta Nat. 2013, 5, 107–115. [Google Scholar] [CrossRef]
  67. Platonova, T.A.; Pridvorova, S.M.; Zherdev, A.V.; Vasilievskaya, L.S.; Arianova, E.A.; Gmoshinski, I.V.; Khotimchenko, S.A.; Dzantiev, B.B.; Popov, V.O.; Tutelyan, V.A. Identification of silver nanoparticles in the samll intestine mucosa, liver and spleen of rats by transmission electron microscopy. Bull. Exp. Biol. Med. 2013, 155, 236–241. [Google Scholar] [CrossRef] [PubMed]
  68. Lewis, R.J. Sax’s Dangerous Properties of Industrial Materials, 9th ed.; Wiley-Interscience: New York, NY, USA, 1998. [Google Scholar]
Pharmaceutics 13 01000 g001 550
Figure 1. HR-TEM micrographs of the five AgNPs studied in this work (a) AgNP1, (b) AgNP2, (c) AgNP3, (d) AgNP4, and (e) AgNP5. The inset on each figure corresponds to the size histogram.
Figure 1. HR-TEM micrographs of the five AgNPs studied in this work (a) AgNP1, (b) AgNP2, (c) AgNP3, (d) AgNP4, and (e) AgNP5. The inset on each figure corresponds to the size histogram.
Pharmaceutics 13 01000 g001
Pharmaceutics 13 01000 g002 550
Figure 2. Surface plasmon resonance (a) and thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) (b) of the five formulations studied in this work. UV-vis spectra were acquired at different concentrations to assure the absorption values were close to unity. TGA and DSC analysis show the weight loss as a function of temperature and the amount of heat required to increase the temperature of the sample, respectively.
Figure 2. Surface plasmon resonance (a) and thermogravimetric analysis (TGA)/differential scanning calorimetry (DSC) (b) of the five formulations studied in this work. UV-vis spectra were acquired at different concentrations to assure the absorption values were close to unity. TGA and DSC analysis show the weight loss as a function of temperature and the amount of heat required to increase the temperature of the sample, respectively.
Pharmaceutics 13 01000 g002
Pharmaceutics 13 01000 g003 550
Figure 3. Cytotoxic effect on HCT-15 cultures after 24 h exposure to 5.5 µM, 55.6µM, 556µM and 5.5 mM of AgNP1–AgNP5. (a) Cell viability, (b) apoptosis, (c) necrosis, and (d) mitochondrial superoxide. * represents statistically significant differences (p < 0.05) compared with negative control, # represents statistically significant differences (p < 0.05) compared with carboplatin, and § represents statistically significant differences (p < 0.05) between the assessed concentrations of each AgNP formulation.
Figure 3. Cytotoxic effect on HCT-15 cultures after 24 h exposure to 5.5 µM, 55.6µM, 556µM and 5.5 mM of AgNP1–AgNP5. (a) Cell viability, (b) apoptosis, (c) necrosis, and (d) mitochondrial superoxide. * represents statistically significant differences (p < 0.05) compared with negative control, # represents statistically significant differences (p < 0.05) compared with carboplatin, and § represents statistically significant differences (p < 0.05) between the assessed concentrations of each AgNP formulation.
Pharmaceutics 13 01000 g003
Pharmaceutics 13 01000 g004 550
Figure 4. Cell viability of mouse primary culture exposed for 24 h to different concentrations (5.5 µM, 55.6 µM, 556 µM and 5.5 mM) of AgNP1–AgNP5 quantified by flow cytometry. (a) Aorta, (b) bone marrow, (c) heart, (d) kidney, (e) liver and (f) spleen. Items (g,h) show the cell viability of monocytes and lymphocytes obtained from the spleen; cell populations differentiated by size and granularity. * represents statistically significant differences (p < 0.05) compared with negative control and § represents statistically significant differences (p < 0.05) between the assessed concentrations of each AgNP formulation.
Figure 4. Cell viability of mouse primary culture exposed for 24 h to different concentrations (5.5 µM, 55.6 µM, 556 µM and 5.5 mM) of AgNP1–AgNP5 quantified by flow cytometry. (a) Aorta, (b) bone marrow, (c) heart, (d) kidney, (e) liver and (f) spleen. Items (g,h) show the cell viability of monocytes and lymphocytes obtained from the spleen; cell populations differentiated by size and granularity. * represents statistically significant differences (p < 0.05) compared with negative control and § represents statistically significant differences (p < 0.05) between the assessed concentrations of each AgNP formulation.
Pharmaceutics 13 01000 g004
Pharmaceutics 13 01000 g005 550
Figure 5. Histological analysis of mice organs exposed to AgNPs formulations AgNP1–AgNP5. The photographs are representative of the damage, when observed, on the lung (a,b); kidney (c,d); liver (e,f); esophagus (g); gastroesophageal union (h); stomach (i,j), and intestine (k,l). Red arrows indicate accumulation of dark non-cellular material. Asterisks show cellular damage.
Figure 5. Histological analysis of mice organs exposed to AgNPs formulations AgNP1–AgNP5. The photographs are representative of the damage, when observed, on the lung (a,b); kidney (c,d); liver (e,f); esophagus (g); gastroesophageal union (h); stomach (i,j), and intestine (k,l). Red arrows indicate accumulation of dark non-cellular material. Asterisks show cellular damage.
Pharmaceutics 13 01000 g005
Table
Table 1. Physicochemical properties for the five AgNP formulations studied in this work.
Table 1. Physicochemical properties for the five AgNP formulations studied in this work.
PropertiesAgNP1AgNP2AgNP3AgNP4AgNP5
Average diameter of metallic cores ØAg (nm)16.4 ± 8.025.4 ± 13.219.0 ± 9.316.4 ± 8.130.6 ± 23.2
TEM size distribution (nm)5–405–605–405–405–80
PVP K-15 aK-17 bK-17 bK-30 c12.6 KDa
Hydrodynamic diameter Øhydro (nm)448.790.443.8483.2121.1
Polydispersity index (PDI)0.8130.2700.4330.5550.280
Zeta potential ζ (mV)−0.872−4.56−5.13−0.464−1.46
Surface plasmon resonance (λ)415402, 444402406, 549429
TGA analysis
Metallic silver (% w/w)1.14 ± 0.021.32 ± 0.051.26 ± 0.031.19 ± 0.011.31± 0.01
PVP (% w/w)19.62 ± 0.3024.49 ± 0.7024.43 ± 0.2020.92 ± 0.4221.67 ± 0.50
H2O (% w/w) 79.24 ± 0.4574.25 ± 0.6075.74 ± 0.2577.89 ± 0.8077.02 ± 0.40
MorphologySphericalSphericalMostly SphericalMostly SphericalSpherical
a K-15: 8000–12,000 kDa; b K-17: 10,000–16,000 kDa; c K-30: 45,000–58,000 kDa.
Table
Table 2. Toxicity signs and median lethal dose (LD50) of AgNP formulations assessed in this work.
Table 2. Toxicity signs and median lethal dose (LD50) of AgNP formulations assessed in this work.
FormulationToxicity Sings 1Lethal Dose (mg/Kg) 2GHS Category 3
AgNP1Slouching, lethargy, hypothermia, dehydration, over-reactive to tactile stimulation.10674
AgNP2Slouching, ruffed hair, vomiting attempt, lethargy, dyspnea, diarrhea, prostration, hypothermia, and seizure. 10674
AgNP3Lethargy, ruffed hair, slouching, and diarrhea.12904
AgNP4Lethargy, slouching, and ruffed hair.18064
AgNP5Lethargy, slouching, ruffed hair, and closed eyes.15484
1 This column shows all the toxicity signs observed with each formulation. 2 The mean lethal dose (LD50) of silver contained on each AgNPs formulation per kilogram of mouse body weight. 3 Classification based on the Globally Harmonized System (GHS) of Classification and Labeling of Chemicals.
Table
Table 3. Histological findings in organs from mice exposed to AgNP1–AgNP5.
Table 3. Histological findings in organs from mice exposed to AgNP1–AgNP5.
AgNP1AgNP2AgNP3AgNP4AgNP5
LungCongestionCongestion
hemorrhage		Congestion
hemorrhage		Congestion
hemorrhage		Congestion
hemorrhage
KidneyFocal hemorrhageFocal hemorrhageFocal hemorrhageFocal hemorrhageFocal hemorrhage
Heart 1CongestionCongestionCongestionCongestionCongestion
Spleen 1CongestionCongestionCongestionCongestionCongestion
Liver 1CongestionCongestionCongestionCongestionCongestion
Esophagus 1Material deposit on the mucosaMaterial deposit on the mucosaMaterial deposit on the mucosaMaterial deposit on the mucosaMaterial deposit on the mucosa
Stomach 1Epithelial
damage		Epithelial
damage		Epithelial
damage		Epithelial
damage		Epithelial
damage
Intestine 1Material deposit on the mucosaMaterial deposit on the mucosaMaterial deposit on the mucosaMaterial deposit on the mucosaMaterial deposit on the mucosa
1 When observed, damage described is diffuse.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Cruz-Ramírez, O.U.; Valenzuela-Salas, L.M.; Blanco-Salazar, A.; Rodríguez-Arenas, J.A.; Mier-Maldonado, P.A.; García-Ramos, J.C.; Bogdanchikova, N.; Pestryakov, A.; Toledano-Magaña, Y. Antitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio. Pharmaceutics 2021, 13, 1000. https://doi.org/10.3390/pharmaceutics13071000

AMA Style

Cruz-Ramírez OU, Valenzuela-Salas LM, Blanco-Salazar A, Rodríguez-Arenas JA, Mier-Maldonado PA, García-Ramos JC, Bogdanchikova N, Pestryakov A, Toledano-Magaña Y. Antitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio. Pharmaceutics. 2021; 13(7):1000. https://doi.org/10.3390/pharmaceutics13071000

Chicago/Turabian Style

Cruz-Ramírez, Omar Ulises, Lucía Margarita Valenzuela-Salas, Alberto Blanco-Salazar, José Antonio Rodríguez-Arenas, Paris A. Mier-Maldonado, Juan Carlos García-Ramos, Nina Bogdanchikova, Alexey Pestryakov, and Yanis Toledano-Magaña. 2021. "Antitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio" Pharmaceutics 13, no. 7: 1000. https://doi.org/10.3390/pharmaceutics13071000

APA Style

Cruz-Ramírez, O. U., Valenzuela-Salas, L. M., Blanco-Salazar, A., Rodríguez-Arenas, J. A., Mier-Maldonado, P. A., García-Ramos, J. C., Bogdanchikova, N., Pestryakov, A., & Toledano-Magaña, Y. (2021). Antitumor Activity against Human Colorectal Adenocarcinoma of Silver Nanoparticles: Influence of [Ag]/[PVP] Ratio. Pharmaceutics, 13(7), 1000. https://doi.org/10.3390/pharmaceutics13071000

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop